Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishesa minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:section/paragraph)	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.	Page 3 Line 52-53 (Material and Methods/Virological Methods). Page 3 Line 62-63 (Material and Methods/Virological Methods) Page 4 Line 76 (Material and methods/Bacterial Cultures) Page 4 Line 82-83 (Material and Methods/Biochemical Markers) Page 4 Line 89-90 (Material and methods/Hematological markers)	

Cell materials	Yes (indicate where provided:section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		N/A. For viral isolation, established cell lines were used and maintained in the virology laboratory itself. Initially supplied by Biomerieux® (Marcy-l'Étoile, France)
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		N/A. Primary cultures were not used for the isolation of the respiratory viruses mentioned in the article. Established lines were used as mentioned above.

Experimental animals	Yes (indicate where provided:section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		N/A. Animals were not tested for this study.
Animal observed in or captured from the field: Provide species, sex and age where possible		N/A. Animals were not tested for this study.
Model organisms: Provide Accession number in repository (where relevant) **OR**		N/A. Animals were not tested for this study.

Plants and microbes	Yes (indicate where provided:	n/a
Plants:provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		N/A. Plants were not used for this study.
Microbes:provide species and strain, unique accession number if available, and source		N/A. Microbes were not used in this study.

Human research participants	Yes (indicate where	n/a
Identify authority granting ethics approval(IRB or equivalent committee(s), provide reference number for approval.	Page 2 Lines 42-43 (Material and Methods/Patients and samples)	

Provide statement confirming informed consent obtained from study participants.		N/A. As it was a retrospective study, the Ethics Committee was asked to exempt informed consent.
Report on age and sex for all study participants.	Sex: Page 2 Line 28 (Material and Methods/Patients and samples) Age: Page 2 Line 32-34 (Material and Methods/Patients and samples)	

Design

Studyprotocol	**Yes (indicate where provided:section/paragraph)**	**n/a**
For clinical trials, provide the trial registration number **OR**cite DOI in manuscript.		N/A. Our study is not a clinical trial, it is a retrospective study.

Laboratoryprotocol	**Yes (indicate where provided:section/paragraph)**	**n/a**
Provide DOI or other citation details if detailed step-by-step protocols are available.		N/A. Detailed step-by-step protocols are not available.

Experimental study design (statistics details)	**Yes (indicate where provided:section/paragraph)**	**n/a**
State whether and how the following have been done**, or** if they were not carried out.		
Sample size determination	Page 2 Lines 25-28 (Material and Methods/Patients and samples)	
Randomisation		N/A. Patients were selected based on inclusion/exclusion criteria
Blinding		N/A. Patients were selected based on inclusion/exclusion criteria.
Inclusion/exclusion criteria	Page 2 Lines 28-32 (Material and Methods/Patients and samples)	

Sample definition and in-laboratory replication	**Yes (indicate where provided:section/paragraph)**	**n/a**
State number of times the experiment was replicated in laboratory		N/A. No replication experiments were performed.
Define whether data describe technical or biological replicates		N/A. No replication experiments were performed.

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Page 2 Lines 42-43 (Material and Methods/Patients and samples)	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		N /A. Our study was not carried out with experimental animals.
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		N / A. Neither specimens nor field samples are involved in our study.

Dual Use Research of Concern (DURC)	Yes (indicate where provided:section/paragraph)	n/a
If study is subject to dual use research ofconcern, statethe authority granting approval and reference number for the regulatory approval		N / A. Study was not subjected to DURC.

Analysis

Attrition	Yes (indicate where	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	Page 2 Line: 25-32 (Material and Methods/Patients and samples).	

Statistics	Yes (indicate where provided:section/paragraph)	n/a
Describestatistical tests used and justify choice of tests.	Page 4 Line 93-97 (Material and Methods/Statistical Analysis)	

Data Availability	Yes (indicate where provided:section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		N/A. If needed, datasets are available by e-mail contact to corresponding author.
If data are publicly available, provide accession number in repository or DOI or URL.		N / A. Data are not publicly repository
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.		N / A. Publicly available data are not rehused.

Code Availability	Yes (indicate where provided:section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:		
State whether the code or software is available.		N / A. No newly generated code was used

If code is publicly available, provide accession number in repository, or DOI or URL.		N / A. No newly generated code was used

Reporting

Adherence to community standards	**Yes (indicate where provided: section/paragraph)**	**n/a**
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/tp-20-333.